<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="46" ids="15035">Retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> is a major component of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> that plays a role in <z:chebi fb="46" ids="15035">retinal</z:chebi> tissue damage in patients with idiopathic <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that type 1 interferons (IFN alpha/beta) were not detected in sera from <z:mpath ids='MPATH_458'>normal</z:mpath> individuals but were identified in up to 46% of the sera from <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>The predominant form of IFN observed was IFN-beta, which was detected in 39% of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patients and 47% of idiopathic <z:hpo ids='HP_0000554'>uveitis</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Seven patients whose sera contained IFN-beta were monitored prospectively </plain></SENT>
<SENT sid="4" pm="."><plain>IFN-beta was shown to be present for 6-12 months in <z:hpo ids='HP_0000001'>all</z:hpo> seven of the sera samples tested </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, the <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule profile identified in this study was strikingly different when <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's and <z:hpo ids='HP_0000554'>uveitis</z:hpo> patient sera were compared to sera from <z:mpath ids='MPATH_458'>normal</z:mpath> controls </plain></SENT>
<SENT sid="6" pm="."><plain>Sera from <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease patients contained significantly elevated levels of the soluble <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, sE-selectin and s-intracellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sICAM-1), whereas sera from patients with idiopathic <z:hpo ids='HP_0000554'>uveitis</z:hpo> contained significantly increased sE-selectin </plain></SENT>
<SENT sid="7" pm="."><plain>In vitro studies evaluating the cell source of these cytokines revealed that polyriboinosinic polyribocytidylic acid (poly I:C) activated <z:chebi fb="46" ids="15035">retinal</z:chebi> vascular endothelial cells produce sE-selectin, sICAM-1 and IFN-beta </plain></SENT>
<SENT sid="8" pm="."><plain>Production of these molecules was inhibited by pretreatment with anti-Toll-like receptor 3 (TLR-3) antibody </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, IFN-beta, sE-selectin and sICAM-1 are elevated in patients with <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> and are induced in <z:chebi fb="46" ids="15035">retinal</z:chebi> vascular endothelial cells in vitro by activating the innate immune system through TLR-3 </plain></SENT>
<SENT sid="10" pm="."><plain>Further analysis of innate immune signalling may prove to be a novel target for future studies on pathogenic mechanisms and therapeutic approaches in <z:chebi fb="46" ids="15035">retinal</z:chebi> <z:hpo ids='HP_0002633'>vasculitis</z:hpo> </plain></SENT>
</text></document>